Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC

Sponsor
Zigong No.1 Peoples Hospital
Study ID
NCT03411967
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    apatinib mesylate tablets 500mg, po, qd, continued until the next cycle, taking on an empty stomach (daily taken at the same time), every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment, apatinib has been taken until the disease progresses, intolerable toxicity.
  • Docetaxel — DRUG
    Docetaxel, 60 mg / m2, d1, iv ,every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment

Study Details

In order to explore a new treatment strategy for patients with failed NSCLC platinum-containing double-drug therapy, this study was to investigate the clinical efficacy of apatinib in combination with docetaxel for patients with advanced NSCLC after failure of platinum-based regime

Key Dates

Start date
Feb 1, 2018
Status verified
Jan 2018
Primary completion
Dec 1, 2020
Completion
Dec 1, 2021

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib combine with docetaxel
    Docetaxel, 60 mg / m2, d1, iv + apatinib 500mg, po, qd

Primary Outcome Measure

ORR [ Time Frame: 6 month ]

Central Contacts

Related Studies